PPH VanEck Pharmaceutical ETF
MVIS US Listed Pharmaceutical 25 NR USD

NAV as of 07-Dec-2022

77.7200

4 Week: 72.70 - 78.22

52 Week: 66.73 - 83.96

Latest Closing Price

78.22

Premium / Discount

-0.13

Expense Ratio

0.35%

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Main Fund Characteristics

Fund Manager:
VanEck
Asset Under Management:
585,709,243
Launch Date:
19/12/2011
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
25
Trading Currency:
USD
Style:
Large Value
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD1.641.111.48
1 Day0.760.000.00
1 Week0.441.120.39
1 Month7.373.941.87
3 Months9.549.131.04
6 Months-0.4612.69-0.04
1 Year6.9617.310.40
2 Years16.9021.030.80
3 Years25.1136.110.70
5 Years34.8242.630.82
10 Years88.6654.011.64

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 12.949036.828223.07643.4122-17.764415.3704-5.523919.01125.380117.8079
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 91.000089.000080.000089.000086.000084.000077.000084.000099.000025.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
02/10/202206/10/20220.2696
30/06/202207/07/20220.2496
31/03/202206/04/20220.4429
28/12/202130/12/20210.2691
30/09/202106/10/20210.3453
30/06/202107/07/20210.2859
31/03/202107/04/20210.3497
28/12/202004/01/20210.2662
31/03/202006/04/20200.3374
29/12/201905/01/20200.1729

Portfolio Data

Total Number of Holdings: 25

Number of Bond Holdings: 0

Number of Equity Holdings: 25

Total Market Value: 585,709,243

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1AbbVie Inc5.7093126,652010,353,801
2AstraZeneca PLC ADR5.4486204,19909,881,190
3Novo Nordisk A/S ADR5.3894173,10909,773,734
4GlaxoSmithKline PLC ADR5.3823215,61509,760,891
5Sanofi SA ADR5.0883202,18309,227,632
6Bristol-Myers Squibb Company5.0703160,86609,195,101
7Pfizer Inc4.9801235,25609,031,478
8Merck & Co Inc4.9714106,14109,015,617
9Eli Lilly and Co4.888878,80108,865,901
10Johnson & Johnson4.853867,09208,802,470

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant66.91
Large13.28
Medium15.65
Small4.17
Micro0.00

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

11.4279

Price/Book*

2.8268

Price/Sales*

1.0152

Price/Cash Flow*

10.2689

Dividend Yield*

2.6195

Growth Measures

Long-Term Earnings

7.5808

Historical Earnings

19.9622

Sales Growth

5.9619

Cash-Flow Growth

6.8200

Book-Value Growth

2.8250

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.